Polyphenol Tetramer Stabilizers for Transthyretin Amyloidosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for transthyretin amyloidosis, such as those using low-molecular-weight compounds that bind to T4 binding sites, are costly and cause side effects, and there is a need for effective preventive measures against the disease, which progresses with high probability due to aging.

Innovation Solution

A polyphenol mixture containing glabridin, glabrene, and glabrol, optionally with 4′-O-methylglabridin, is used to stabilize transthyretin tetramers, suppressing amyloid fibril formation, administered in forms like tablets, capsules, or powders, with specific peak intensity ratios in HPLC analysis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If low-molecular-weight compounds are used to stabilize transthyretin tetramer, then stabilization effect is achieved, but cost per dose increases and side effects occur

Engineering Contradiction:

Improvetransthyretin tetramer stabilizationVSAvoidside effects and cost burden

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention changes the chemical structure parameters of the stabilizing compound by introducing fluorine atoms at specific positions (e.g., 2-fluoro-4-(trifluoromethyl)phenyl group) and modifying the R1-R6 substituents on the xanthene ring system. These parameter changes optimize the binding affinity to transthyretin while reducing off-target effects and metabolic instability, thereby achieving better stabilization with reduced side effects and cost

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite molecular structure combining a xanthene core with specific aromatic substituents containing fluorine atoms and heteroatoms. This composite structure integrates multiple functional groups that work synergistically: the xanthene core provides the basic binding scaffold, while the fluorinated aromatic groups enhance binding affinity and selectivity, resulting in a stabilizer with improved efficacy and reduced adverse effects

Inventive Principle:

Principle #40Composite materials

2Reliability

If transthyretin tetramer stabilization is pursued to prevent amyloidosis, then disease prevention is possible, but existing compounds involve high cost burden on patients

Engineering Contradiction:

Improveamyloidosis preventionVSAvoidcost per dose

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The invention optimizes the molecular parameters of the stabilizing compound by adjusting the substituents R1-R6 on the xanthene ring, introducing fluorine atoms at strategic positions, and modifying the aromatic groups. These parameter changes improve the drug's pharmacokinetic properties and binding efficiency, allowing for lower dosing requirements and reduced manufacturing costs while maintaining effective amyloidosis prevention

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention designs a small-molecule compound with a simplified structure compared to protein-based therapeutics, using abundant elements like carbon, hydrogen, fluorine, and common heteroatoms. This approach enables cost-effective synthesis through established organic chemistry methods, making the preventive treatment more economically accessible while maintaining sufficient stability for the intended therapeutic duration

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If transthyretin tetramer stabilization is achieved, then amyloid fibril formation is suppressed, but complete cure is difficult once disease develops

Engineering Contradiction:

Improveamyloid fibril suppressionVSAvoiddisease progression reversibility

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The invention is designed for early intervention before amyloid fibrils form and cause irreversible damage. The stabilizing compound binds to transthyretin tetramers in their native state, preventing dissociation into monomers that would otherwise misfold and aggregate into amyloids. By acting preliminarily on the tetramer structure before pathological changes occur, the compound can prevent disease development entirely or suppress progression at early stages when reversal is still possible

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The polyphenol mixture stabilizes transthyretin tetramers, preventing monomerization and amyloid fibril formation, effectively treating or preventing transthyretin amyloidosis, including conditions like familial amyloid polyneuropathy and senile systemic amyloidosis.

Implementation Method 1

two molecules of glabridin, which is one of licorice glabra polyphenols, have the effect of binding to and stabilizing a transthyretin tetramer

Methodology Applied

Scientific EffectMolecular binding:

Data Source

PatentUS12629350B2Transthyretin tetramer stabilizing agent, and preventing agent or progression suppressing agent for transthyretin amyloidosis

Publication Date: 2026.05.19 KANEKA CORP

AI summary

Provided are a transthyretin tetramer stabilizing agent and a preventing agent or progression suppressing agent for transthyretin amyloidosis. The present invention relates to a transthyretin tetramer stabilizing agent including glabridin, glabrene, and glabrol, and to a preventing agent or progression suppressing agent for transthyretin amyloidosis including glabridin, glabrene, and glabrol.